Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 04 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predicting in-hospital mortality in cirrhosis with systemic inflammatory response syndrome

Low eosinophil count predicts in-hospital mortality in cirrhosis with systemic inflammatory response syndrome, reports June's issue of the European Journal of Gastroenterology & Hepatology.

News image

Absolute eosinophil count and procalcitonin level may have a prognostic value in critically ill patients.

However, their role in cirrhotic patients has never been studied.

Dr Hardik Kotecha and colleagues evaluated the role of absolute eosinophil count and procalcitonin, obtained at admission, in predicting in-hospital mortality in cirrhotic patients with systemic inflammatory response syndrome.

The research team estimated levels of absolute eosinophil count and procalcitonin were estimated at admission in 100 patients.

Their outcome was correlated with these baseline parameters.

The doctors examined that etiology of cirrhosis was alcohol, cryptogenic, viral, and others.

Their median model for end-stage liver disease and Child–Turcotte–Pugh scores were 24 and 11, respectively.

The researchers noted that infection was present in 59 patients, and the rest of the 41 patients had systemic inflammatory response syndrome without infection.

63 patients recovered from systemic inflammatory response syndrome
European Journal of Gastroenterology & Hepatology

There was a significant difference between the median levels of absolute eosinophil count, and procalcitonin between patients who had infection, and those who did not have infection.

The doctors found that 63 patients recovered from systemic inflammatory response syndrome, and were discharged, 33 patients died, and 4 patients received orthotopic liver transplantation during the same admission.

Baseline absolute eosinophil count and procalcitonin levels were significantly different between patients who recovered and died.

On multivariate analysis, baseline absolute eosinophil count values could independently predict in-hospital mortality, in addition to model for end-stage liver disease and serum sodium.

The area under receiver operating characteristic curve of absolute eosinophil count for predicting mortality was 0.785, and the best cutoff of absolute eosinophil count, obtained by Youden’s index, was 104 cells/cumm, indicating that patients with baseline absolute eosinophil count values less than 104 cells/cumm had higher in-hospital mortality.

Dr Hardik's team commented, "In critically ill cirrhotic patients with systemic inflammatory response syndrome, a baseline absolute eosinophil count value of less than 104 cells/cumm accurately predicts in-hospital mortality."

"The prediction of mortality by Absolute eosinophil count is independent of the model for end-stage liver disease score and serum sodium."

Euro J of Gastroenterol & Hepatol 2013: 25(6): 676-682
13 June 2013

Go to top of page Email this page Email this page to a colleague

 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 29 November 2016 
Treating Zenker's diverticulum
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants
 08 November 2016 
NSAIDS and risk of Barrett’s
 08 November 2016 
Ferritin levels and NAFLD mortality
 08 November 2016 
Alarms in the diagnosis of colorectal cancer
 07 November 2016 
BMI and fibrosis regression during Hep B
 07 November 2016 
Prognosis and biliary tract malignancies
 07 November 2016 
Post-colonoscopy colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us